Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | BRAF amp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04201457 | Phase Ib/II | Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | Recruiting | USA | 0 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Recruiting | CAN | 0 |
NCT03843775 | Phase Ib/II | Binimetinib + Encorafenib | A Study of Binimetinib and Encorafenib in Advanced BRAF Mutant Cancers | Recruiting | USA | 0 |
NCT03989115 | Phase Ib/II | Cobimetinib + RMC-4630 Osimertinib + RMC-4630 | Dose-Escalation/Expansion of RMC-4630 and Cobimetinib in Relapsed/Refractory Solid Tumors and RMC-4630 and Osimertinib in EGFR Positive Locally Advanced/Metastatic NSCLC | Active, not recruiting | USA | 1 |
NCT01514864 | Phase II | Dasatinib | Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Terminated | USA | DEU | CAN | 4 |
NCT03634982 | Phase I | RMC-4630 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Recruiting | USA | 0 |
NCT04322383 | Phase II | Binimetinib | Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | Recruiting | USA | 0 |
NCT02508077 | Phase II | Fluorouracil + Irinotecan + Leucovorin Panitumumab | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT04616183 | Phase Ib/II | Abemaciclib + Cetuximab + LY3214996 Cetuximab + LY3214996 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04619316 | Phase II | Dabrafenib + Trametinib Trametinib | Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition (ERRITI) | Recruiting | DEU | 0 |
NCT02138292 | Phase I | Digoxin + Trametinib | A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT04129515 | Phase Ib/II | Pembrolizumab | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | Not yet recruiting | USA | 0 |
NCT01138085 | Phase I | Trametinib + Uprosertib | Safety, Pharmacokinetics (PK) of AKT and MEK Combination | Completed | USA | 0 |
NCT02785068 | Phase I | Fluorouracil + Irinotecan + Leucovorin + MM-151 | Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer | Withdrawn | 0 | |
NCT03069950 | Phase II | Dexamethasone + Floxuridine + Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver | Withdrawn | USA | 0 |
NCT04744831 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | 5 |
NCT03149029 | Phase II | Dabrafenib + Pembrolizumab + Trametinib Pembrolizumab + Trametinib | Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma | Active, not recruiting | USA | 0 |
NCT03384940 | Phase II | Trastuzumab deruxtecan | DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01) | Completed | USA | ITA | ESP | 2 |
NCT01802320 | Phase II | MK2206 | Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT03457896 | Phase II | Cetuximab + Neratinib Neratinib + Trastuzumab | Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status | Active, not recruiting | USA | 0 |
NCT03978611 | Phase I | Ipilimumab + Relatlimab | A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment | Recruiting | USA | FRA | ESP | DEU | CAN | BEL | 0 |
NCT01960023 | Phase Ib/II | Cetuximab + Neratinib | Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer | Withdrawn | USA | 0 |
NCT01941927 | Phase II | Trametinib + Uprosertib | Trametinib With GSK2141795 in BRAF Wild-type Melanoma | Completed | USA | 0 |
NCT04434560 | Phase II | Ipilimumab + Nivolumab | Neoadjuvant Immunotherapy in Brain Metastases | Terminated | USA | 0 |
NCT03878719 | Phase I | Binimetinib + Encorafenib | Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma | Recruiting | USA | ITA | 3 |
NCT02318901 | Phase Ib/II | Ado-trastuzumab emtansine + Pembrolizumab Pembrolizumab + Trastuzumab Cetuximab + Pembrolizumab | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer | Terminated | USA | 0 |
NCT03580382 | Phase Ib/II | CDX-3379 + Trametinib | Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | Terminated | USA | 0 |
NCT04488003 | Phase II | Ulixertinib | Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations | Recruiting | USA | 0 |
NCT04390243 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation | Recruiting | USA | 0 |
NCT02465060 | Phase II | Erdafitinib Trametinib Crizotinib Sapanisertib AZD4547 Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Recruiting | USA | 2 |
NCT04589845 | Phase II | Alectinib Ado-trastuzumab emtansine Ipatasertib GDC-0077 Entrectinib Atezolizumab Idasanutlin | Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT04249843 | Phase I | BGB3245 | Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors | Recruiting | USA | 1 |
NCT05111561 | Phase I | Binimetinib + ZEN-3694 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | Recruiting | USA | 0 |
NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
NCT04985604 | Phase Ib/II | MLN2480 | DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors | Recruiting | USA | 0 |
NCT04534283 | Phase II | Abemaciclib + LY3214996 | A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib. | Recruiting | USA | 0 |
NCT02296112 | Phase II | Trametinib | Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations | Completed | USA | 0 |
NCT02285439 | Phase Ib/II | Binimetinib | Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors | Active, not recruiting | USA | 0 |
NCT04201457 | Phase Ib/II | Hydroxychloroquine + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration | Recruiting | USA | 0 |
NCT04923126 | Phase Ib/II | PD-0325901 | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT04418167 | Phase I | JSI-1187 Dabrafenib + JSI-1187 | JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations | Recruiting | USA | 0 |
NCT01777776 | Phase Ib/II | Encorafenib Encorafenib + Ribociclib | Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. | Terminated | USA | CAN | 2 |
NCT04543188 | Phase I | Binimetinib + Midazolam + PF-07284890 Binimetinib + PF-07284890 PF-07284890 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | Recruiting | USA | 0 |
NCT03377361 | Phase Ib/II | Regorafenib Ipilimumab + Nivolumab + Trametinib Nivolumab + Trametinib | An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (CheckMate 9N9) | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 6 |
NCT01826448 | Phase I | Pexidartinib + Vemurafenib | A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma | Terminated | USA | FRA | DEU | 0 |
NCT01738451 | Phase I | Dabrafenib | A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors | Completed | USA | 2 |
NCT01677741 | Phase I | Dabrafenib | A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects | Completed | USA | ITA | FRA | ESP | DEU | CAN | 4 |
NCT05099003 | Phase Ib/II | Selinexor | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Recruiting | USA | 0 |
NCT03297606 | Phase II | Bosutinib Palbociclib Vismodegib Ipilimumab + Nivolumab Cobimetinib + Vemurafenib Temsirolimus Olaparib Erlotinib Crizotinib Sunitinib Afatinib Dasatinib Pertuzumab + Trastuzumab Axitinib | Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) | Recruiting | CAN | 0 |
NCT01902173 | Phase Ib/II | Dabrafenib + Trametinib + Uprosertib Dabrafenib + Uprosertib | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | Active, not recruiting | USA | 0 |
NCT05356897 | Phase II | Trastuzumab + Trifluridine-tipiracil hydrochloride + Tucatinib | Tucatinib Combined With Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | Not yet recruiting | USA | 0 |
NCT02723006 | Phase I | MLN2480 + Nivolumab MLN1202 + Nivolumab Ipilimumab + Nivolumab + Vedolizumab | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | Terminated | USA | 0 |
NCT03992456 | Phase II | Panitumumab Regorafenib Trifluridine-tipiracil hydrochloride | Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer | Recruiting | USA | 0 |
NCT02428712 | Phase Ib/II | PLX8394 | A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors | Recruiting | USA | 0 |
NCT03273153 | Phase III | Pembrolizumab Atezolizumab + Cobimetinib | A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | Completed | USA | ITA | FRA | ESP | DEU | BEL | 9 |
NCT04952753 | Phase II | Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + NIS793 Bevacizumab + Fluorouracil + Leucovorin + NIS793 + Oxaliplatin | Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3) | Recruiting | USA | FRA | ESP | DEU | 7 |
NCT03592641 | Phase II | Savolitinib | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT02906059 | Phase I | Adavosertib + Irinotecan | Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT01683188 | Phase III | Aldesleukin + Vemurafenib | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma | Terminated | USA | 0 |
NCT02967692 | Phase III | Dabrafenib + Spartalizumab + Trametinib Dabrafenib + Trametinib | A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 21 |
NCT03220035 | Phase II | Vemurafenib | Pediatric MATCH: Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations | Active, not recruiting | USA | 1 |
NCT04294160 | Phase I | Dabrafenib + LTT462 + Spartalizumab Dabrafenib + LTT462 + TNO155 Dabrafenib + TNO155 + Trametinib Dabrafenib + LTT462 Dabrafenib + LTT462 + LXH 254 Dabrafenib + LTT462 + Trametinib | A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer | Recruiting | USA | ESP | DEU | CAN | BEL | 5 |
NCT03581292 | Phase II | Temozolomide + Veliparib Veliparib | Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations | Active, not recruiting | USA | CAN | 3 |
NCT01974258 | Phase I | Onartuzumab + Vemurafenib Cobimetinib + Onartuzumab Cobimetinib + Onartuzumab + Vemurafenib | Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients | Withdrawn | USA | 0 |
NCT05180825 | Phase II | Vinblastine Trametinib | Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) | Not yet recruiting | FRA | 0 |
NCT03543969 | Phase I | Cobimetinib + Vemurafenib | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma | Recruiting | USA | 0 |
NCT04190628 | Phase I | ABM-1310 | Safety of ABM-1310 Monotherapy in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT01739764 | Phase III | Vemurafenib | An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT01843738 | Phase I | Vemurafenib | Radiation Use During Vemurafenib Treatment | Withdrawn | USA | 0 |
NCT04462471 | Phase I | Copanlisib + Vemurafenib | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | Recruiting | USA | 0 |
NCT01942993 | Phase II | Vemurafenib | The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma | Terminated | USA | 0 |
NCT05388877 | Phase I | Dabrafenib + E6201 | E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma | Not yet recruiting | USA | 0 |
NCT03793179 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pemetrexed Disodium | Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | Recruiting | USA | CAN | 1 |
NCT02230306 | Phase II | Cobimetinib + Vemurafenib | Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases | Terminated | USA | 0 |
NCT02263898 | Phase II | Binimetinib + Encorafenib | Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations | Withdrawn | USA | 0 |
NCT04528836 | Phase I | IACS-13909 | First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Not yet recruiting | USA | 0 |
NCT05299580 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR) | Recruiting | ITA | 0 |
NCT01813214 | Phase II | Vemurafenib | The Effects of Vemurafenib on Immunity in Patients With Melanoma | Terminated | USA | 0 |
NCT04302025 | Phase II | Cobimetinib + Vemurafenib Entrectinib Atezolizumab Alectinib Pralsetinib | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01946789 | Phase I | ALT-803 | A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT01619774 | Phase II | Dabrafenib + Trametinib | An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor | Completed | USA | 0 |
NCT02068079 | Phase I | Trientine + Vemurafenib | A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma | Withdrawn | USA | 0 |
NCT03911869 | Phase II | Binimetinib + Encorafenib | An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis (POLARIS) | Terminated | USA | ITA | BEL | 2 |
NCT02974803 | Phase II | Dabrafenib + Trametinib | Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases | Terminated | CAN | 0 |
NCT01835184 | Phase I | Cabozantinib + Vemurafenib | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | Terminated | USA | 0 |
NCT04544111 | Phase II | Dabrafenib + Spartalizumab Spartalizumab + Trametinib | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | Recruiting | USA | 0 |
NCT01562899 | Phase II | Binimetinib + Ganitumab | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | Terminated | USA | ITA | FRA | ESP | CAN | BEL | 2 |
NCT01524978 | Phase II | Vemurafenib Cetuximab | A Study of Zelboraf (Vemurafenib) in Patients With BRAF V600 Mutation-Positive Cancers | Completed | USA | FRA | ESP | DEU | 2 |
NCT01543698 | Phase Ib/II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Ribociclib | A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | CAN | BEL | 3 |
NCT03087071 | Phase II | Panitumumab Panitumumab + Trametinib | Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer | Unknown status | USA | 0 |
NCT01656642 | Phase I | Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Vemurafenib | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | Completed | USA | 0 |
NCT02039947 | Phase II | Dabrafenib + Trametinib | Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain | Completed | USA | ITA | FRA | ESP | DEU | CAN | 1 |
NCT01767623 | Phase I | Vemurafenib | A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Patients | Completed | USA | 6 |
NCT04587128 | Phase II | Cetuximab Cetuximab + Irinotecan Panitumumab Irinotecan + Panitumumab | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | Recruiting | USA | 0 |
NCT03919071 | Phase II | Dabrafenib + Trametinib | Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma | Recruiting | USA | 1 |
NCT02456701 | Phase I | CDX-3379 + Vemurafenib | Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379 | Completed | USA | 0 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | 1 |
NCT04375527 | Phase II | Binimetinib + Nivolumab | Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma | Recruiting | USA | 0 |
NCT04324112 | Phase II | Binimetinib + Encorafenib | Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | Recruiting | USA | 0 |
NCT05275374 | Phase Ib/II | BI 882370 + Trametinib BI 882370 | XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE) | Not yet recruiting | 0 | |
NCT05215340 | Phase III | Pembrolizumab Datopotamab Deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | 2 |
NCT01787500 | Phase I | Cetuximab + Irinotecan + Vemurafenib | Vemurafenib, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT03301636 | Phase II | Indoximod + Nivolumab Indoximod + Pembrolizumab | A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma (NLG2107) | Terminated | USA | 0 |
NCT02036086 | Phase II | Cobimetinib + Vemurafenib | Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases | Active, not recruiting | CAN | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Active, not recruiting | USA | 0 |
NCT01701037 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery | Terminated | USA | 0 |
NCT03442569 | Phase II | Ipilimumab + Nivolumab + Panitumumab | PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC | Active, not recruiting | USA | 0 |
NCT02961283 | Phase I | ASN003 | Study of ASN003 in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT01954043 | Phase I | Dabrafenib + Rabeprazole + Rifampin | A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors | Completed | USA | 2 |
NCT03332589 | Phase I | Dabrafenib + E6201 E6201 | E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) | Terminated | USA | 0 |
NCT04145297 | Phase I | Hydroxychloroquine + Ulixertinib | Ulixertinib (BVD-523) and Hydroxychloroquine in Patients w Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas (UTAH) | Recruiting | USA | 0 |
NCT04903119 | Phase I | Dabrafenib + Nilotinib + Trametinib | Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma | Recruiting | USA | 0 |
NCT05355701 | Phase I | Binimetinib + PF-07799933 PF-07799933 Cetuximab + PF-07799933 | A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors. | Not yet recruiting | USA | 0 |
NCT02721459 | Phase I | Cobimetinib + Vemurafenib + XL888 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | Active, not recruiting | USA | 0 |
NCT01894672 | Phase II | Encorafenib | BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation | Completed | USA | 0 |
NCT02159066 | Phase II | Binimetinib + Encorafenib + Ribociclib Binimetinib + Encorafenib Binimetinib + Capmatinib + Encorafenib Binimetinib + Buparlisib + Encorafenib Binimetinib + Encorafenib + Infigratinib | LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | Active, not recruiting | USA | ITA | ESP | DEU | CAN | 4 |
NCT01907802 | Phase I | Dabrafenib | Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction | Terminated | USA | CAN | 0 |
NCT04511013 | Phase II | Ipilimumab + Nivolumab Binimetinib + Encorafenib + Nivolumab | A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Recruiting | USA | 0 |
NCT02094872 | Phase II | Doxorubicin | Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic | Completed | USA | 0 |
NCT04059224 | Phase II | Dabrafenib + Trametinib | TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma (TraMel-WT) | Recruiting | BEL | 0 |
NCT01436656 | Phase I | Encorafenib | A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma | Active, not recruiting | FRA | ESP | 2 |
NCT03005639 | Phase II | Cobimetinib + Vemurafenib | ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma | Withdrawn | USA | 0 |
NCT02145910 | Phase I | Vemurafenib | Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases | Withdrawn | 0 | |
NCT01844674 | Phase I | Tizanidine + Vemurafenib | A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies | Completed | USA | CAN | 3 |
NCT02278133 | Phase Ib/II | Cetuximab + Encorafenib + LGK974 | Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations | Completed | USA | ITA | FRA | ESP | CAN | BEL | 4 |
NCT01820364 | Phase II | Binimetinib + Encorafenib Encorafenib + Ribociclib Buparlisib + Encorafenib Encorafenib + Infigratinib Capmatinib + Encorafenib | LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma | Terminated | USA | ESP | DEU | CAN | 2 |
NCT01603212 | Phase Ib/II | Aldesleukin + Alpha 2 Interferon + Vemurafenib | Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor | Completed | USA | 0 |
NCT04741997 | Phase I | Binimetinib + Encorafenib + Nivolumab Binimetinib + Encorafenib | Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Recruiting | USA | 0 |
NCT03446157 | Phase II | Cetuximab + Palbociclib | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT04417621 | Phase II | LTT462 + LXH 254 Trametinib Ribociclib | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | Active, not recruiting | USA | ITA | FRA | DEU | BEL | AUT | 7 |
NCT03178851 | Phase I | Atezolizumab Atezolizumab + Cobimetinib | Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma | Completed | USA | ESP | 5 |
NCT01981187 | Phase II | Encorafenib | LGX818 for Patients With BRAFV600 Mutated Tumors | Terminated | USA | 0 |
NCT03754179 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2) | Recruiting | BEL | 0 |
NCT03864042 | Phase I | Caffeine + Dextromethorphan + Losartan + Midazolam + Omeprazole Modafinil Bupropion + Rosuvastatin Binimetinib + Encorafenib | Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors | Recruiting | USA | ESP | CAN | BEL | 1 |
NCT02314481 | Phase II | Vemurafenib Atezolizumab Alectinib Ado-trastuzumab emtansine | Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (DARWINII) | Recruiting | 1 | |
NCT01519323 | Phase I | Vemurafenib | BRIM-P | Terminated | USA | ITA | FRA | ESP | DEU | 5 |
NCT04720768 | Phase Ib/II | Binimetinib + Encorafenib + Palbociclib | Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE) | Recruiting | 1 | |
NCT02145143 | Phase 0 | Vemurafenib | Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study | Active, not recruiting | USA | 0 |
NCT02082665 | Phase I | Dabrafenib + Midazolam + Rosuvastatin | Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam | Completed | USA | ESP | 0 |
NCT02124772 | Phase I | Trametinib Dabrafenib + Trametinib | Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations | Completed | USA | FRA | CAN | 2 |
NCT02908672 | Phase III | Cobimetinib + Vemurafenib Atezolizumab + Cobimetinib + Vemurafenib | A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT01765543 | Phase I | Rifampin + Vemurafenib | A Pharmacokinetics Study to Investigate the Effect of Rifampin on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy | Completed | USA | 4 |
NCT04484142 | Phase II | Datopotamab Deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 5 |
NCT04487106 | Phase II | Azacitidine + Trametinib + Venetoclax | Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome | Recruiting | USA | 0 |
NCT04644237 | Phase II | Trastuzumab deruxtecan | Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) | Active, not recruiting | USA | ITA | FRA | ESP | CAN | 5 |
NCT04222972 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Pralsetinib Cisplatin + Gemcitabine Carboplatin + Gemcitabine Cisplatin + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium | A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 18 |
NCT04984811 | Phase II | Atezolizumab + NT-I7 | NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | Recruiting | USA | 0 |
NCT05200481 | Phase II | Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | Recruiting | FRA | 0 |
NCT03088176 | Phase I | Dabrafenib + Talimogene laherparepvec + Trametinib | Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma | Active, not recruiting | USA | 0 |
NCT04526691 | Phase I | Cisplatin + Datopotamab Deruxtecan + Pembrolizumab Carboplatin + Datopotamab Deruxtecan + Pembrolizumab Datopotamab Deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | Recruiting | USA | ITA | ESP | 2 |
NCT04811001 | Phase II | Dacomitinib Osimertinib | Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations (CAPLAND) | Recruiting | ITA | 0 |
NCT02140840 | Phase II | Trametinib | A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib | Withdrawn | USA | 0 |
NCT03516981 | Phase II | MK-1308 + Pembrolizumab MK-4280 + Pembrolizumab Lenvatinib + Pembrolizumab | A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495) | Active, not recruiting | USA | ITA | ESP | CAN | 12 |
NCT01586195 | Phase II | Vemurafenib | Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E | Terminated | USA | 0 |
NCT04166487 | Phase II | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab + Pemetrexed Disodium | Plasma-Adapted First-Line Pembro In NSCLC | Recruiting | USA | 0 |
NCT03310541 | Phase I | Capivasertib Capivasertib + Enzalutamide Capivasertib + Fulvestrant | AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations | Active, not recruiting | USA | 0 |
NCT04683250 | Phase Ib/II | TAS0953/HM06 | Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities | Recruiting | USA | 1 |
NCT02012231 | Phase Ib/II | PLX8394 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | Terminated | USA | 0 |
NCT03429803 | Phase I | MLN2480 | DAY101 In Gliomas and Other Tumors | Active, not recruiting | USA | 0 |
NCT02367859 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma | Completed | USA | 0 |
NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Recruiting | DEU | 0 |
NCT04775485 | Phase II | MLN2480 | A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma (FIREFLY-1) | Recruiting | USA | DEU | CAN | 8 |
NCT04108026 | Phase II | Durvalumab | Immunotherapy in Patient With Poor General Condition (SAVIMMUNE) | Recruiting | FRA | 0 |
NCT02949843 | Phase II | Nivolumab + Pembrolizumab | Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations | Terminated | USA | 0 |
NCT01596140 | Phase I | Temsirolimus + Vemurafenib Everolimus + Vemurafenib | Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer | Completed | USA | 0 |
NCT05340621 | Phase Ib/II | Binimetinib + OKI-179 | OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) | Recruiting | USA | 0 |
NCT03665129 | Phase I | Durvalumab + IPH5401 | IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors (STELLAR-001) | Terminated | USA | FRA | 0 |
NCT04169841 | Phase II | Durvalumab + Olaparib + Tremelimumab | Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment (GUIDE2REPAIR) | Recruiting | FRA | 0 |
NCT03114319 | Phase I | TNO155 | Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | CAN | 5 |
NCT05313009 | Phase Ib/II | Sotorasib + TH-4000 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Recruiting | USA | 0 |
NCT04612751 | Phase I | Datopotamab Deruxtecan + Durvalumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Carboplatin in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04) | Recruiting | USA | FRA | 1 |
NCT04467801 | Phase II | Ipatasertib Docetaxel + Ipatasertib | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy | Recruiting | USA | 0 |
NCT05006794 | Phase I | GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 | Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies | Recruiting | USA | 0 |
NCT01713972 | Phase I | Dabrafenib + Pazopanib | Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors | Completed | USA | 0 |
NCT04699188 | Phase Ib/II | JDQ443 JDQ443 + TNO155 JDQ443 + Spartalizumab JDQ443 + Spartalizumab + TNO155 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |
NCT01636622 | Phase I | Carboplatin + Paclitaxel + Vemurafenib | Study of Vemurafenib, Carboplatin, and Paclitaxel | Completed | USA | 0 |
NCT04913285 | Phase I | Binimetinib + KIN-2787 KIN-2787 | A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors | Recruiting | USA | ESP | 1 |
NCT02693535 | Phase II | Cobimetinib + Vemurafenib Atezolizumab + Talazoparib Regorafenib Larotrectinib Trastuzumab + Tucatinib Ipilimumab + Nivolumab Palbociclib Afatinib Entrectinib Talazoparib Pembrolizumab Temsirolimus Pertuzumab + Trastuzumab Atezolizumab + Pertuzumab/trastuzumab/hyaluronidase-zzxf Crizotinib Abemaciclib Sunitinib Olaparib | TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR) | Recruiting | USA | 0 |
NCT03235245 | Phase II | Binimetinib + Encorafenib Ipilimumab + Nivolumab | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (EBIN) | Recruiting | ITA | FRA | ESP | DEU | BEL | 3 |
NCT04557956 | Phase Ib/II | Tazemetostat Dabrafenib + Tazemetostat + Trametinib | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Recruiting | USA | 0 |
NCT03915951 | Phase II | Binimetinib + Encorafenib | An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | Active, not recruiting | USA | ITA | ESP | 2 |
NCT01659151 | Phase II | Aldesleukin Fludarabine Vemurafenib | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 Metastatic Melanoma | Active, not recruiting | USA | 0 |
NCT02130466 | Phase Ib/II | Dabrafenib + Trametinib Pembrolizumab + Trametinib Dabrafenib + Pembrolizumab Dabrafenib + Pembrolizumab + Trametinib | A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | Completed | 0 | |
NCT03973918 | Phase II | Binimetinib + Encorafenib | Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) | Active, not recruiting | USA | 0 |
NCT04074096 | Phase II | Binimetinib + Encorafenib + Pembrolizumab | Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis (BEPCOME-MB) | Not yet recruiting | FRA | 0 |
NCT04759846 | Phase I | Binimetinib + Encorafenib | Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma | Not yet recruiting | ITA | ESP | 1 |
NCT02257424 | Phase Ib/II | Dabrafenib + Hydroxychloroquine + Trametinib | Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM) | Completed | USA | 0 |
NCT04310397 | Phase II | Dabrafenib + Trametinib Dabrafenib + Spartalizumab + Trametinib | Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma | Active, not recruiting | USA | 0 |
NCT05097378 | Phase II | Binimetinib + Encorafenib | Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM) | Not yet recruiting | 1 | |
NCT03975231 | Phase I | Dabrafenib + Trametinib | Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT03898908 | Phase II | Binimetinib + Encorafenib | Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain (EBRAIN-MEL) | Recruiting | ESP | 0 |
NCT04551521 | Phase II | Atezolizumab Atezolizumab + Ipatasertib Atezolizumab + Pertuzumab + Trastuzumab Atezolizumab + Cobimetinib Alectinib Atezolizumab + Cobimetinib + Vemurafenib | CRAFT: The NCT-PMO-1602 Phase II Trial | Recruiting | DEU | 0 |
NCT04657991 | Phase III | Pembrolizumab Binimetinib + Encorafenib + Pembrolizumab | A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | Recruiting | USA | ITA | ESP | DEU | 6 |
NCT01682213 | Phase II | Dabrafenib | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | Completed | USA | 0 |
NCT03455764 | Phase Ib/II | Dabrafenib + MCS110 + Trametinib | MCS110 With BRAF/MEK Inhibition in Patients With Melanoma | Active, not recruiting | USA | 0 |
NCT04527549 | Phase II | Dabrafenib + Trametinib Dabrafenib + Hydroxychloroquine + Trametinib | Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | Active, not recruiting | USA | 0 |
NCT02027961 | Phase Ib/II | Dabrafenib + Durvalumab + Trametinib Durvalumab + Trametinib | Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone | Completed | USA | ITA | FRA | CAN | 0 |
NCT03026517 | Phase I | Dabrafenib + Phenformin + Trametinib | Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma | Active, not recruiting | USA | 0 |
NCT01657591 | Phase I | Vemurafenib + XL888 | Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma | Active, not recruiting | USA | 0 |
NCT01781026 | Phase II | Vemurafenib | Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases | Completed | USA | 0 |
NCT01495988 | Phase II | Bevacizumab Vemurafenib | Trial of Vemurafenib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | Terminated | USA | 0 |
NCT02200562 | Phase Ib/II | Dabrafenib + Ipilimumab | Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma | Terminated | USA | 0 |
NCT02818023 | Phase I | Cobimetinib + Pembrolizumab + Vemurafenib | Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | Terminated | USA | 0 |
NCT02427893 | Phase III | Cobimetinib Vemurafenib | Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma | Withdrawn | USA | 0 |
NCT03272464 | Phase I | Dabrafenib + Itacitinib + Trametinib | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors. | Active, not recruiting | USA | 0 |
NCT01909453 | Phase III | Vemurafenib Encorafenib Binimetinib + Encorafenib | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | 23 |
NCT03101254 | Phase Ib/II | Cobimetinib + LY3022855 + Vemurafenib | LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma | Active, not recruiting | USA | 0 |
NCT01947023 | Phase I | Dabrafenib + Lapatinib | Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01767454 | Phase I | Dabrafenib + Ipilimumab + Trametinib Dabrafenib + Ipilimumab | Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma | Completed | USA | 0 |
NCT02097225 | Phase I | Dabrafenib + Onalespib + Trametinib | Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT02224781 | Phase III | Ipilimumab + Nivolumab Dabrafenib + Trametinib | Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma | Active, not recruiting | USA | 0 |
NCT03551626 | Phase III | Dabrafenib + Trametinib | Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes (COMBI-APlus) | Completed | ITA | FRA | CAN | 20 |
NCT01940809 | Phase II | Dabrafenib + Ipilimumab Ipilimumab + Nivolumab + Trametinib Dabrafenib + Ipilimumab + Trametinib Ipilimumab + Trametinib Dabrafenib + Ipilimumab + Nivolumab Ipilimumab Ipilimumab + Nivolumab Dabrafenib + Ipilimumab + Nivolumab + Trametinib | Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery | Terminated | USA | 0 |
NCT04655157 | Phase Ib/II | Encorafenib + Ipilimumab + Nivolumab Binimetinib + Encorafenib + Ipilimumab + Nivolumab | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma (QUAD01) | Recruiting | USA | 0 |
NCT01978236 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites | Terminated | USA | 1 |
NCT01989585 | Phase Ib/II | Dabrafenib + Navitoclax + Trametinib Dabrafenib + Trametinib | Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma | Active, not recruiting | USA | 0 |
NCT01512251 | Phase Ib/II | Buparlisib + Vemurafenib | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | Completed | USA | 0 |
NCT01585415 | Phase I | Vandetanib | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | Terminated | USA | 0 |
NCT02196181 | Phase II | Dabrafenib + Trametinib | Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT01682083 | Phase III | Dabrafenib + Trametinib | Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 17 |
NCT01877811 | Phase Ib/II | RXDX-105 | CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2 | Completed | USA | 0 |
NCT03175224 | Phase Ib/II | Bozitinib | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA) | Recruiting | USA | ITA | FRA | ESP | CAN | 9 |
NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Recruiting | FRA | 0 |
NCT03244956 | Phase II | Trametinib Dabrafenib + Trametinib | Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer (MERAIODE) | Active, not recruiting | FRA | 0 |
NCT01876641 | Phase Ib/II | Decitabine + Vemurafenib | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib | Terminated | USA | 0 |
NCT03181100 | Phase II | Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab Atezolizumab + Nab-paclitaxel Atezolizumab + Cobimetinib + Vemurafenib Atezolizumab + Paclitaxel | Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT01721603 | Phase II | Dabrafenib | A Phase 2 Prospective Trial of Dabrafenib With Stereotactic Radiosurgery in BRAFV600E Melanoma Brain Metastases | Terminated | USA | 0 |
NCT03708328 | Phase I | RO7121661 | A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors | Active, not recruiting | USA | FRA | ESP | 3 |
NCT05241873 | Phase Ib/II | BLU-451 | Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Recruiting | USA | 0 |
NCT04862780 | Phase Ib/II | BLU-945 | Study Targeting EGFR Resistance Mechanisms in NSCLC | Recruiting | USA | ESP | 6 |
NCT02915666 | Phase I | Dabrafenib + Digoxin + Trametinib | A Clinical Trial of Patients With Melanoma | Withdrawn | USA | 0 |
NCT04238624 | Phase II | Cemiplimab + Dabrafenib + Trametinib | Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT01748149 | Phase I | Vemurafenib | Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas | Active, not recruiting | USA | CAN | 0 |
NCT04800822 | Phase I | PF-07284892 Cetuximab + Encorafenib + PF-07284892 Lorlatinib + PF-07284892 Binimetinib + PF-07284892 | PF-07284892 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT04140500 | Phase I | RO7247669 | Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors | Recruiting | USA | ESP | 6 |
NCT05223673 | Phase III | Trifluridine-tipiracil hydrochloride Futuximab + Modotuximab | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer (COLSTAR) | Not yet recruiting | USA | BEL | 2 |
NCT05388123 | Phase II | Rituximab + Vemurafenib | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | Recruiting | USA | 0 |
NCT01943422 | Phase Ib/II | Interferon alpha-2b + Vemurafenib | Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma | Completed | USA | 0 |
NCT01534897 | Phase I | Dabrafenib | Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436 | Completed | USA | 0 |
NCT03475004 | Phase II | Bevacizumab + Binimetinib + Pembrolizumab | Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT03224767 | Phase II | Cobimetinib + Vemurafenib | Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma | Recruiting | USA | 0 |
NCT03668431 | Phase II | Dabrafenib + Spartalizumab + Trametinib | Dabrafenib + Trametinib + PDR001 In Colorectal Cancer | Recruiting | USA | 0 |
NCT04034459 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Cetuximab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC (AIO-KRK-0116) | Active, not recruiting | DEU | 0 |
NCT02143050 | Phase Ib/II | Dabrafenib + Metformin + Trametinib | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | Recruiting | USA | 0 |
NCT03334617 | Phase II | AZD9150 + Durvalumab Durvalumab + Olaparib Cediranib + Durvalumab Durvalumab + Vistusertib Durvalumab + Trastuzumab deruxtecan Ceralasertib + Durvalumab | Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON) | Recruiting | USA | FRA | ESP | DEU | CAN | AUT | 2 |
NCT04117945 | Phase II | Regorafenib Irinotecan + Panitumumab Panitumumab Cetuximab + Irinotecan Cetuximab | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT03365882 | Phase II | Cetuximab + Irinotecan Pertuzumab + Trastuzumab | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | Active, not recruiting | USA | 1 |
NCT04787341 | Phase II | Regorafenib Panitumumab | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence (PARERE) | Recruiting | ITA | 0 |
NCT04126733 | Phase II | Nivolumab + Regorafenib | Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable) | Completed | USA | 0 |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 7 |
NCT05005273 | Phase II | Ipilimumab + Nivolumab BMS-986207 + Ipilimumab + Nivolumab | A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer | Not yet recruiting | USA | ITA | FRA | ESP | DEU | BEL | 7 |
NCT05330429 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Bevacizumab + Fluorouracil + Hu5F9-G4 + Irinotecan + Leucovorin | Study of Magrolimab Given Together With FOLFIRI/BEV in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Recruiting | USA | 0 |
NCT04017650 | Phase Ib/II | Cetuximab + Encorafenib + Nivolumab | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | Recruiting | USA | 0 |
NCT02164916 | Phase II | Cetuximab + Irinotecan Cetuximab + Irinotecan + Vemurafenib | S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | 0 |
NCT04151563 | Phase Ib/II | Lucitanib + Nivolumab Docetaxel Cabozantinib + Nivolumab Cabozantinib + Ipilimumab + Nivolumab Docetaxel + Nivolumab Docetaxel + Nivolumab + Ramucirumab | A Phase 1/2 Study Evaluating Multiple Nivolumab Combination Therapy in Participants With Stage IV Non-small Cell Lung Cancer That Has Spread or Has Reoccurred After Failure of Chemotherapy and Immunotherapy | Withdrawn | USA | BEL | 8 |
NCT01089101 | Phase Ib/II | Selumetinib | Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma | Active, not recruiting | USA | 0 |
NCT05064280 | Phase II | Lenvatinib Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Recruiting | USA | 0 |
NCT01336634 | Phase II | Dabrafenib Dabrafenib + Trametinib | Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer. | Completed | USA | ITA | FRA | ESP | DEU | 6 |
NCT03631706 | Phase II | M7824 Pembrolizumab | M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 11 |
NCT04166409 | Phase III | Selumetinib Carboplatin + Vincristine Sulfate | A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma | Recruiting | USA | CAN | 1 |
NCT04526782 | Phase II | Docetaxel Binimetinib + Encorafenib | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | Recruiting | FRA | 0 |
NCT02014909 | Phase I | CDX-3379 CDX-3379 + Vemurafenib CDX-3379 + Trastuzumab CDX-3379 + Cetuximab CDX-3379 + Erlotinib | A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors | Completed | USA | 0 |
NCT01754376 | Phase II | Aldesleukin + Vemurafenib | Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma | Terminated | USA | 0 |
NCT03255083 | Phase I | DS-1205c + Osimertinib | DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer | Terminated | 1 | |
NCT03693170 | Phase II | Binimetinib + Cetuximab + Encorafenib | Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer (ANCHOR-CRC) | Active, not recruiting | USA | ITA | FRA | ESP | BEL | AUT | 3 |
NCT04044430 | Phase Ib/II | Binimetinib + Encorafenib + Nivolumab | Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer | Active, not recruiting | USA | 0 |
NCT01897116 | Phase I | Hydroxychloroquine + Vemurafenib | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | Completed | USA | 0 |
NCT03803553 | Phase III | Binimetinib + Cetuximab + Encorafenib Nivolumab Fluorouracil + Irinotecan + Leucovorin | Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | Recruiting | USA | 0 |
NCT04995523 | Phase Ib/II | AZD2936 | A Study to Assess the Safety and Efficacy of AZD2936 in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (ARTEMIDE-01) | Recruiting | ESP | BEL | 5 |
NCT03189030 | Phase I | pLADD | Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer | Terminated | USA | 0 |
NCT01709292 | Phase II | Vemurafenib | Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04607421 | Phase III | Bevacizumab + Capecitabine + Oxaliplatin Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin Cetuximab + Encorafenib Cetuximab + Encorafenib + Fluorouracil + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Encorafenib + Fluorouracil + Irinotecan + Leucovorin | A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Recruiting | USA | ITA | ESP | DEU | CAN | BEL | 23 |
NCT04268550 | Phase II | Selpercatinib | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | Recruiting | USA | 0 |
NCT01638676 | Phase Ib/II | Metformin + Vemurafenib | A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients | Recruiting | USA | 0 |
NCT01740648 | Phase I | Fluorouracil + Trametinib | Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer | Active, not recruiting | USA | 0 |
NCT04585815 | Phase Ib/II | Axitinib + PF-06801591 + SGN-TGT Binimetinib + Encorafenib + PF-06801591 | A Study of Sasanlimab With Other Therapies in People With Non-small Cell Lung Cancer | Recruiting | USA | CAN | BEL | 3 |
NCT04576117 | Phase III | Selumetinib Selumetinib + Vinblastine | A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma | Recruiting | USA | CAN | 0 |
NCT05217446 | Phase II | Pembrolizumab Cetuximab + Encorafenib + Pembrolizumab | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (SEAMARK) | Not yet recruiting | 1 | |
NCT05039177 | Phase Ib/II | Cetuximab + Encorafenib + ERAS-007 ERAS-007 + Palbociclib | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies (HERKULES-3) | Recruiting | USA | 0 |
NCT01711632 | Phase II | Vemurafenib | BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | Active, not recruiting | USA | 0 |
NCT05048797 | Phase III | Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Trastuzumab deruxtecan | A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 12 |
NCT02675946 | Phase I | CGX1321 CGX1321 + Pembrolizumab Cetuximab + CGX1321 + Encorafenib | CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596) | Recruiting | USA | 1 |
NCT03520686 | Phase III | ALT-803 + Carboplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Cisplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab ALT-803 + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium ALT-803 + Carboplatin + Nab-paclitaxel + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Recruiting | USA | 0 |
NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Active, not recruiting | USA | 0 |
NCT01750918 | Phase II | Fluorouracil Dabrafenib + Panitumumab Dabrafenib + Panitumumab + Trametinib Panitumumab + Trametinib | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | Completed | USA | ITA | FRA | ESP | BEL | 3 |
NCT03840915 | Phase Ib/II | Cisplatin + M7824 + Pemetrexed Disodium Docetaxel + M7824 Carboplatin + M7824 + Pemetrexed Disodium Cisplatin + Gemcitabine + M7824 Carboplatin + Gemcitabine + M7824 Carboplatin + M7824 + Nab-paclitaxel | M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | USA | FRA | BEL | 0 |
NCT05026983 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | Recruiting | USA | 0 |
NCT04675710 | Phase II | Dabrafenib + Pembrolizumab + Trametinib | Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer | Recruiting | USA | 0 |
NCT01726738 | Phase II | Dabrafenib + Trametinib | LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations | Completed | USA | 0 |
NCT04252339 | Phase I | RLY-1971 | RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | 0 |
NCT02034110 | Phase II | Dabrafenib + Trametinib | Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 6 |
NCT04061980 | Phase II | Binimetinib + Encorafenib Binimetinib + Encorafenib + Nivolumab | Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer | Recruiting | USA | 0 |
NCT03732703 | Phase Ib/II | Dexamethasone + Enasidenib + Ixazomib + Pomalidomide Cobimetinib + Dexamethasone + Ixazomib + Pomalidomide Dexamethasone + Erdafitinib + Ixazomib + Pomalidomide Dexamethasone + Ixazomib + Pomalidomide + Venetoclax Abemaciclib + Dexamethasone + Ixazomib + Pomalidomide Daratumumab + Dexamethasone + Ixazomib + Pomalidomide | Myeloma-Developing Regimens Using Genomics (MyDRUG) | Recruiting | USA | 0 |
NCT02178722 | Phase Ib/II | Epacadostat + Pembrolizumab | Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | Completed | USA | 0 |
NCT05059470 | Phase II | Pembrolizumab | IMRT Followed by Pembrolizumab in the Adjuvant Setting in Anaplastic Cancer of the Thyroid (IMPAACT): Phase II Trial Adjuvant Pembrolizumab After IMRT in ATC | Active, not recruiting | USA | 0 |
NCT03138889 | Phase Ib/II | NKTR-214 + Pembrolizumab Carboplatin + Nab-paclitaxel + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Paclitaxel + Pembrolizumab Cisplatin + NKTR-214 + Pembrolizumab Carboplatin + NKTR-214 + Pembrolizumab + Pemetrexed Disodium | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | ITA | FRA | ESP | DEU | 1 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 9 |
NCT02928224 | Phase III | Cetuximab + Encorafenib Binimetinib + Cetuximab + Encorafenib Cetuximab + Irinotecan Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (BEACON CRC) | Active, not recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT | 19 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Active, not recruiting | USA | 1 |
NCT04623775 | Phase II | Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium Cisplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab Carboplatin + Nab-paclitaxel + Nivolumab + Pemetrexed Disodium + Relatlimab Carboplatin + Nivolumab + Paclitaxel + Pemetrexed Disodium + Relatlimab | A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Recruiting | USA | ITA | FRA | ESP | DEU | BEL | AUT | 14 |
NCT03608046 | Phase II | Avelumab + Cetuximab + Irinotecan | Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer (AVETUXIRI) | Recruiting | BEL | 0 |
NCT05182931 | Phase II | Dabrafenib + Trametinib Trametinib | A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (I-FIRST) | Not yet recruiting | 1 | |
NCT04655976 | Phase II | Docetaxel Docetaxel + Dostarlimab-gxly + TSR-022 Docetaxel + Dostarlimab-gxly | Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | 11 |
NCT04171622 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer | Not yet recruiting | USA | 0 |
NCT02065063 | Phase I | Palbociclib + Trametinib | A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors | Completed | USA | 0 |
NCT03874026 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients (CIFRA) | Recruiting | ITA | 0 |
NCT01231594 | Phase I | Dabrafenib Trametinib | A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | Completed | USA | ITA | FRA | ESP | DEU | CAN | 3 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Active, not recruiting | USA | FRA | 2 |
NCT01723202 | Phase II | Dabrafenib + Trametinib Dabrafenib | Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT04105270 | Phase II | Carboplatin + Durvalumab + Pemetrexed Disodium Cisplatin + Durvalumab + Pemetrexed Disodium Durvalumab | P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC | Not yet recruiting | USA | 0 |
NCT05259319 | Phase I | Atezolizumab + Tiragolumab | Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) (IMMUNOs-SBRT) | Not yet recruiting | FRA | 0 |
NCT04370704 | Phase Ib/II | INCAGN02385 + INCAGN02390 + Retifanlimab INCAGN02385 + INCAGN02390 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | Recruiting | USA | 0 |
NCT04925986 | Phase II | Pembrolizumab + Sitravatinib | Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC | Recruiting | USA | 0 |
NCT03559049 | Phase Ib/II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + Rucaparib | Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04425239 | Phase II | Fluorouracil + Irinotecan + Leucovorin + Panitumumab | Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE) | Completed | ITA | 0 |
NCT03037385 | Phase Ib/II | Pralsetinib | Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) | Active, not recruiting | USA | ITA | ESP | DEU | 7 |
NCT01306045 | Phase II | Erlotinib Lapatinib MK2206 Sunitinib Selumetinib | Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | Active, not recruiting | USA | 0 |
NCT02860780 | Phase I | Prexasertib + Ralimetinib | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | Completed | USA | DEU | 0 |
NCT01781429 | Phase Ib/II | Ulixertinib | Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies | Completed | USA | 0 |
NCT03867799 | Phase II | Nivolumab + Relatlimab | iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer | Active, not recruiting | 1 | |
NCT04609566 | Phase II | Brentuximab vedotin + Pembrolizumab | Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | Recruiting | USA | 0 |
NCT01885195 | Phase II | Binimetinib | MEK162 for Patients With RAS/RAF/MEK Activated Tumors | Completed | USA | 0 |
NCT04515394 | Phase II | Cetuximab + Tepotinib | Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE) | Terminated | USA | ITA | FRA | ESP | BEL | 3 |
NCT04524689 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium + SAR408701 Cisplatin + Pemetrexed Disodium + SAR408701 Carboplatin + Pembrolizumab + SAR408701 Pembrolizumab + SAR408701 Cisplatin + Pembrolizumab + SAR408701 | Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05) | Recruiting | USA | FRA | ESP | 4 |
NCT04566393 | Expanded access | Ulixertinib | Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies | Available | USA | 0 |
NCT03696212 | Phase Ib/II | Grapiprant + Pembrolizumab | Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma | Terminated | USA | 0 |
NCT04511845 | Phase I | SPYK04 | A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). | Recruiting | USA | 1 |
NCT01719380 | Phase Ib/II | Cetuximab + Encorafenib Alpelisib + Cetuximab + Encorafenib | Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer | Completed | USA | ITA | FRA | ESP | DEU | CAN | BEL | 5 |
NCT03391232 | Phase I | PolyPEPI1018 | Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO) | Completed | USA | ITA | 0 |
NCT02648490 | Phase I | Acetaminophen + Dexamethasone + Diphenhydramine + Ondansetron HLX07 | An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers | Completed | USA | 1 |
NCT04189055 | Phase II | Cetuximab + Irinotecan Cetuximab | Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL) | Recruiting | FRA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT04457284 | Phase II | Cisplatin + Nivolumab + Temozolomide | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | Recruiting | USA | 0 |
NCT01531361 | Phase I | Sorafenib + Vemurafenib Crizotinib + Vemurafenib | Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | Completed | USA | 0 |
NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Active, not recruiting | USA | 2 |
NCT01037790 | Phase II | Palbociclib | PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER | Completed | USA | 0 |
NCT01449058 | Phase Ib/II | Alpelisib + Binimetinib | A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | ITA | FRA | ESP | 3 |
NCT04656652 | Phase III | Docetaxel Datopotamab Deruxtecan | Study of DS-1062A Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01) | Recruiting | USA | ITA | FRA | ESP | DEU | CAN | BEL | 19 |
NCT01351103 | Phase I | LGK974 LGK974 + Spartalizumab | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | Recruiting | USA | ESP | 1 |
NCT02050321 | Phase II | Acitretin + Vemurafenib | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | Terminated | USA | 0 |
NCT03213691 | Phase II | Selumetinib | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03162627 | Phase I | Olaparib + Selumetinib | Selumetinib and Olaparib in Solid Tumors | Recruiting | USA | 0 |
NCT03091257 | Phase I | Dabrafenib + Trametinib Dabrafenib Trametinib | A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma | Recruiting | USA | 0 |
NCT04892017 | Phase Ib/II | DCC-3116 + Sotorasib Binimetinib + DCC-3116 DCC-3116 DCC-3116 + Trametinib | A Phase 1/2 Study of DCC-3116 as Monotherapy and Combination Therapy in Patients With MAPK Pathway Mutant Solid Tumors | Recruiting | USA | 0 |
NCT05312398 | Phase II | Cetuximab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Irinotecan Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin | CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen | Recruiting | ITA | 0 |
NCT04620330 | Phase II | Defactinib + RO5126766 RO5126766 | A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer | Recruiting | USA | ITA | FRA | ESP | DEU | 0 |
NCT03972046 | Phase II | Dabrafenib + Talimogene laherparepvec + Trametinib | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma | Withdrawn | USA | 0 |
NCT02974725 | Phase I | LXH 254 + Ribociclib LXH 254 + Trametinib LTT462 + LXH 254 | A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma | Active, not recruiting | USA | ITA | FRA | ESP | DEU | BEL | 5 |
NCT03664024 | Phase II | Pembrolizumab + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium | Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) (KEYNOTE-782) | Completed | USA | ESP | CAN | 2 |
NCT01744652 | Phase I | Crizotinib + Dasatinib | Dasatinib and Crizotinib in Advanced Cancer | Completed | USA | 0 |
NCT02610361 | Phase I | BGB-283 | Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors | Completed | 2 | |
NCT04409639 | Phase II | Cobimetinib | Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations (CONCERTO) | Recruiting | USA | 0 |
NCT01841463 | Phase Ib/II | Vemurafenib + Voruciclib | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | Suspended | USA | 0 |
NCT04495621 | Phase Ib/II | Cetuximab + CH5132799 | MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) | Recruiting | USA | ITA | FRA | ESP | DEU | 2 |
NCT04776655 | Phase III | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin Cetuximab + Fluorouracil + Irinotecan + Leucovorin | Study in mCRC Patients RAS/BRAF wt Tissue and RAS Mutated LIquid BIopsy to Compare FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb) | Recruiting | ITA | 0 |
NCT04921358 | Phase III | Docetaxel Sitravatinib + Tislelizumab | Tislelizumab in Combination With Sitravatinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Recruiting | 2 | |
NCT05291156 | Phase II | Cetuximab Avelumab + Cetuximab | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | Not yet recruiting | ITA | 0 |
NCT03051035 | Phase I | KO-947 | First-in-Human Study of KO-947 in Non-Hematological Malignancies | Terminated | USA | ESP | 0 |
NCT02747537 | Phase II | Irinotecan + Sorafenib | Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan | Withdrawn | 0 | |
NCT03555149 | Phase Ib/II | Atezolizumab Atezolizumab + Isatuximab Atezolizumab + Bevacizumab + PGG beta-glucan | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC) | Recruiting | USA | FRA | ESP | 4 |
NCT00770263 | Phase I | Erlotinib + Temsirolimus | Erlotinib and Temsirolimus for Solid Tumors | Completed | USA | 0 |
NCT03218826 | Phase I | AZD8186 + Docetaxel | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | Active, not recruiting | USA | 0 |
NCT04072198 | Phase II | Bevacizumab + Fluorouracil + Irinotecan + Leucovorin + Nivolumab + Oxaliplatin | Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients (NIVACOR) | Recruiting | ITA | 0 |
NCT04591431 | Phase II | Everolimus Nivolumab Itacitinib Erlotinib Ponatinib Pemigatinib Ipatasertib Ipilimumab Cobimetinib Atezolizumab Palbociclib Entrectinib Vemurafenib Lapatinib Trastuzumab Brigatinib Alectinib Ado-trastuzumab emtansine Pertuzumab Vismodegib | The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy (ROME) | Recruiting | ITA | 0 |
NCT03784378 | Phase I | RXDX-105 | Continued Access to RXDX-105 | Completed | USA | 0 |
NCT03415126 | Phase I | ERAS-007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02407509 | Phase I | RO5126766 Everolimus + RO5126766 | Phase I Trial of RO5126766 Alone and in Combination With Everolimus (RAF/MEK) | Recruiting | 1 | |
NCT03396497 | Phase I | LYC-55716 + Pembrolizumab | Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer | Unknown status | USA | 0 |
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |